Under the agreement, Monsanto grants Dow AgroSciences a nonexclusive, royalty-bearing license in the United States to develop, produce, sell and sublicense seed and germplasm with RR2Y technology. Dow also receives an option to license the technology in other countries like Brazil, where Monsanto plans to commercialize this technology after obtaining regulatory approval.

Dow gains the rights to stack RR2Y technology with other biotechnology traits. Dow also gains the rights to out-license its germplasm containing RR2Y technology, alone or in stacks, to third parties that hold Genuity RR2Y licenses from Monsanto.